Increase in Nonfatal Digestive Perforations and Haemorrhages Following Introduction of Selective NSAIDs

This publication has 18 references indexed in Scilit:

• National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release
  Archives of internal medicine (1960), 2005
• Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial
  Gastroenterology, 2004
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
  The Lancet, 2004
• Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland
  Pharmacoepidemiology and Drug Safety, 2003
• Use of NSAIDs, COX‐2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population
  Arthritis Care & Research, 2002
• Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
  BMJ, 2002
• Update of ACR Guidelines for Osteoarthritis: Role of the Coxibs
  Journal of Pain and Symptom Management, 2002
• Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects
  Gut, 2002
• Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
  2000
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000